" JAK2 V617F Mutation in Cervical Cancer Related to HPV & STIs" - Letter

Affiliations

Comment

Stephen E Langabeer. J Cancer Prev. 2019 Mar.

. 2019 Mar;24(1):59-60.

doi: 10.15430/JCP.2019.24.1.59. Epub 2019 Mar 30.

No abstract available

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflicts of interest were disclosed.

Characterization of JAK2 V617F (1849 G > T) Mutation in Cervical Cancer Related to Human Papillomavirus and Sexually Transmitted Infections.
Abdolmaleki M, Sohrabi A. Abdolmaleki M, et al. J Cancer Prev. 2018 Jun;23(2):82-86. doi: 10.15430/JCP.2018.23.2.82. Epub 2018 Jun 30. J Cancer Prev. 2018. PMID: 30003068 Free PMC article.

1. Abdolmaleki M, Sohrabi A. Characterization of JAK2 V617F (1849 G > T) mutation in cervical cancer related to human papillomavirus and sexually transmitted infections. J Cancer Prev 2018;23:82–6.10.15430/JCP.2018.23.2.82 - DOI - PMC - PubMed
1. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673–83.10.1038/nrc2210 - DOI - PubMed
1. Shepard GC, Lawson HL, Hawkins GA, Owen J. BsaXI/RFLP analysis of initial or selectively reamplified PCR product is unreliable in detecting the V617F mutation in JAK2. Int J Lab Hematol 2011;33:267–71.10.1111/j.1751-553X.2010.01282.x - DOI - PubMed
1. Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, et al. Molecular diagnostics of myeloproliferative neoplasms. Eur J Haematol 2015;95:270–9.10.1111/ejh.12578 - DOI - PubMed
1. Zhang Z, Fye S, Borecki IB, Rader JS. Polymorphisms in immune mediators associate with risk of cervical cancer. Gynecol Oncol 2014;135:69–73.10.1016/j.ygyno.2014.07.106 - DOI - PMC - PubMed